What is Aspira Womens Health Net Current Asset Value?
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Aspira Womens Health's net current asset value per share for the quarter that ended in Mar. 2024 was €-0.18.
The historical rank and industry rank for Aspira Womens Health's Net Current Asset Value or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Aspira Womens Health was 408.00. The lowest was 3.46. And the median was 7.85.
FRA:CUL's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 4.3 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
Aspira Womens Health Net Current Asset Value Historical Data
The historical data trend for Aspira Womens Health's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Aspira Womens Health Net Current Asset Value Chart
Competitive Comparison of Aspira Womens Health's Net Current Asset Value
For the Diagnostics & Research subindustry, Aspira Womens Health's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Womens Health's Price-to-Net-Current-Asset-Value Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Aspira Womens Health's Price-to-Net-Current-Asset-Value falls into.
Aspira Womens Health Net Current Asset Value Calculation
Aspira Womens Health's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Womens Health (FRA:CUL) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Aspira Womens Health Net Current Asset Value Related Terms
Thank you for viewing the detailed overview of Aspira Womens Health's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Aspira Womens Health (FRA:CUL) Business Description
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:CUL has been successfully added to your 